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Abstract
Placing a patient in a state of general anesthesia is crucial for safely and humanely performing
most surgical and many nonsurgical procedures. How anesthetic drugs create the state of general
anesthesia is considered a major mystery of modern medicine. Unconsciousness, induced by
altered arousal and/or cognition, is perhaps the most fascinating behavioral state of general
anesthesia. We perform a systems neuroscience analysis of the altered arousal states induced by
five classes of intravenous anesthetics by relating their behavioral and physiological features to the
molecular targets and neural circuits at which these drugs are purported to act. The altered states
of arousal are sedation-unconsciousness, sedation-analgesia, dissociative anesthesia, pharmaco-
logic non-REM sleep, and neuroleptic anesthesia. Each altered arousal state results from the
anesthetic drugs acting at multiple targets in the central nervous system. Our analysis shows that
general anesthesia is less mysterious than currently believed.
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Introduction
The practice of administering general anesthesia, which began nearly 165 years ago,
revolutionized medicine by transforming surgery from trauma and butchery into a humane
therapy (Bigelow 1846, Long 1849, Fenster 2001, Boland 2009). In the United States, 21
million patients receive general anesthesia each year for surgical procedures alone (Jt.
Comm. 2004). General anesthesia is also essential for conducting many nonsurgical
diagnostic and therapeutic procedures. Significant improvements have been made in
anesthetic drugs (Schuttler & Schwilden 2008), monitoring standards (Eichhorn et al. 1986),
monitoring devices (Ali et al. 1970, 1971; Tremper & Barker 1989; Kearse et al. 1994), and
delivery systems (Wuesten 2001, Sloan 2002). Nevertheless, debate continues in
Copyright © 2011 by Annual Reviews. All rights reserved
Disclosure Statement: The authors are not aware of any affiliations, memberships, funding, or financial holdings that might be
perceived as affecting the objectivity of this review.
NIH Public Access
Author Manuscript
Annu Rev Neurosci. Author manuscript; available in PMC 2012 July 06.
Published in final edited form as:
Annu Rev Neurosci. 2011 ; 34: 601–628. doi:10.1146/annurev-neuro-060909-153200.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
anesthesiology over how best to define general anesthesia (Eger 1993, Kissin 1993). How
anesthetic drugs create the state of general anesthesia is considered one of the biggest
mysteries of modern medicine (Kennedy & Norman 2005).
Studies of the mechanisms of general anesthesia focus on characterizing the actions of
anesthetic drugs at molecular targets in the central nervous system (Hemmings et al. 2005,
Grasshoff et al. 2006, Franks 2008). This work has been crucial for identifying molecular
and pharmacological principles that underlie anesthetic drugs and for establishing the
existence of multiple mechanisms of anesthetic action. Studies of the pharmacokinetic and
pharmaco-dynamic properties of anesthetics provide the main guidelines for drug dosing
(Shafer et al. 2009). Neurophysiological (Angel 1991, 1993; Gredell et al. 2004; Velly et al.
2007; Bieda et al. 2009; Breshears et al. 2010) and functional imaging studies of general
anesthesia (Alkire et al. 1995, Veselis et al. 1997, Bonhomme et al. 2001, Purdon et al.
2009, Mhuircheartaigh et al. 2010) are helping to identify the neural circuits involved in
creating the states of general anesthesia. Furthermore, the behavioral and physiological
changes observed when anesthetics are administered in clinical practice provide important
insights into their mechanisms. Deciphering the mechanisms of general anesthesia requires a
systems neuroscience analysis—that is, relating the actions of the drugs at specific
molecular targets in specific neural circuits to the behavioral and physiological states that
comprise general anesthesia (Brown 2007).
To develop such an analysis we define general anesthesia as a drug-induced, reversible
condition composed of the behavioral states of unconsciousness, amnesia, analgesia, and
immobility along with physiological stability (Brown et al. 2010). Of the behavioral states,
unconsciousness is perhaps the most fascinating. Patients often admit that the unknown of
being unconscious is their biggest fear about undergoing general anesthesia.
Unconsciousness can be achieved by altering a patient's level of arousal and/or cognition.
Anesthesiologists use different drugs to alter arousal in order to create the state of general
anesthesia. We review the altered arousal states of five classes of intravenous anesthetic
drugs: gamma-amino butyric acid type A (GABAA) receptor agonists, opioid receptor
agonists, N-methyl D-aspartate receptor (NMDA) antagonists, alpha 2 receptor agonists, and
dopamine receptor antagonists. We demonstrate that each altered arousal state can be
characterized in terms of its specific behavioral and physiological features, as well as the
molecular targets and neural circuits in which the drugs are purported to act. For each drug,
we summarize these features in a table at the end of each section.
Sedation and Unconsciousness: GABAA Receptor Agonists
Clinical Features of Altered Arousal of GABAA Agonists
The anesthetic drugs that act as agonists at GABAA receptors are used primarily to induce
sedation or unconsciousness. These drugs, which include propofol, sodium thiopental,
methoxital, and etomidate, belong to different drug classes. Propofol is 2,6 di-isopropyl-
phenol (James & Glen 1980), sodium thiopental and methohexital are barbiturates (Russo &
Bressolle 1998), and etomidate is a carboxylated imidazole derivative (Vanlersberghe &
Camu 2008). All act at GABAA receptors to enhance inhibition. Their effects depend on
how much and how rapidly they are administered.
Administration of small doses of a GABAA hypnotic induces sedation. If the dose is
increased slowly, the patient can enter a state of paradoxical excitation or disinhibition
defined by euphoria or dysphoria, incoherent speech, purposeless or defensive movements,
and increased electroencephalogram (EEG) oscillations in the beta range (13–25 Hz).
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The excitatory state is termed paradoxical because a drug given to induce sedation or
unconsciousness results in excitation (Brown et al. 2010). Paradoxical excitation frequently
occurs when GABAA agonists are administered as sedatives for colonoscopies, dental
extractions, or radiological procedures (Fulton & Mullen 2000, Tung et al. 2001).
Methohexitalis distinct from other hypnotics because small doses of it can induce seizures
(Rockoff & Goudsouzian 1981). Therefore, methohexital is used as an induction agent
during electroconvulsive therapy because the therapeutic benefit of this procedure is related
to the quality of the seizure activity it induces (Avramov et al. 1995). Low-dose
methohexital is also used during cortical mapping studies to help identify seizure foci
(Hufnagel et al. 1992).
If the hypnotic is administered as a bolus dose over 5 to 10 seconds, as is typical for
induction of general anesthesia, then within 20 to 30 seconds, the patient becomes
unresponsive to verbal commands, regular breathing transitions to apnea, and ventilation by
bag and mask must be started to support breathing (Brown et al. 2010). Loss of
consciousness can be easily tracked during drug administration on induction by having the
patient execute a cognitive task such as counting backward or performing smooth eye
pursuit of the anesthesiologist's finger. Patients counting backward rarely go beyond 10
digits. With loss of consciousness, the smooth pursuit excursions decrease then stop;
blinking increases; nystagmus may appear; and the eyelash, corneal and oculocephalic
reflexes are lost. The pupillary response to light remains intact (Brown et al. 2010). With
propofol, a concomitant loss of skeletal muscle tone occurs (Brown et al. 2010), whereas
with etomidate, the loss of muscle tone may be preceded by myoclonus (Van Keulen &
Burton 2003). The EEG typically shows alpha and delta oscillations or burst suppression.
The vasodilatory and myocardial depressant effects of the hypnotic drugs generally cause a
decrease in blood pressure that leads to a baroreceptor reflex-mediated increase in heart rate.
An opioid is frequently administered prior to or during induction to help mitigate the rise in
heart rate, and vasopressors may be administered to maintain blood pressure. After the
anesthesiologist administers a muscle relaxant, the patient is intubated, and maintenance of
general anesthesia is achieved by a combination of inhalational agents, opioids, hypnotic
agents, muscle relaxants, sedatives, and cardiovascular medications with ventilation and
thermoregulatory support.
Mechanisms of GABAA-Mediated Altered Arousal
GABAA receptors are widely distributed throughout the brain (Bowery et al. 1987).
Molecular studies have identified GABAA receptors as the targets of anesthetic drugs
(Hemmings et al. 2005, Grasshoff et al. 2006). Binding of a GABAA hypnotic to the GABA
receptors helps maintain postsynaptic chloride channels in the open position, thereby
enhancing the inward chloride current, which hyperpolarizes the pyramidal neurons (Bai et
al. 1999). For example, a pyramidal neuron in the cortex receives excitatory inputs from
each of the major cholinergic, monoaminergic, and orexinergic arousal pathways as well as
inhibitory inputs from local inhibitory interneurons (Figure 1a). During wakefulness, there is
a balance between the pyramidal neuron's excitatory and inhibitory inputs. Because small
numbers of inhibitory interneurons control large numbers of excitatory pyramidal neurons,
hypnotic-induced enhancement of GABAA inhibition can efficiently inactivate large brain
regions (Figure 1b) (Markram et al. 2004). Several neurophysiological and imaging studies
support the idea that cortical sites are targets of GABAergic hypnotics (Angel 1991, Alkire
et al. 1995, Velly et al. 2007, Purdon et al. 2009, Breshears et al. 2010, Ferrarelli et al.
2010).
When administered as a bolus for induction of general anesthesia, the hypnotic rapidly
reaches the GABAergic neurons in the respiratory centers in the pons and medulla (Feldman
et al. 2003) and the arousal centers in the pons, midbrain, hypothalamus and basal forebrain
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(Saper et al. 2005) (Figure 2a). The clinical signs are consistent with inhibitory actions in the
brainstem. Loss of the oculocephalic and corneal reflexes is a nonspecific indicator of
impaired brain-stem function due to the actions of the hypnotic agent on the nuclei that
control eye movements in the midbrain and pons (Posner et al. 2007). Basic science studies
have shown that unconsciousness can result from direct injection of a barbiturate into the
mesopontine tegmental area (Devor & Zalkind 2001). Brain injury studies show that
brainstem coma typically involves bilateral lesions in either the midbrain or pontine
tegementum (Parvizi & Damasio 2003). The preoptic area (POA) of the hypothalamus
provides GABAergic inhibition to the principal arousal centers in the hypothalamus,
midbrain, and pons (Saper et al. 2005) (Figure 1a). These GABAergic synapses onto
pyramidal cells in the arousal centers are likely sites of action of the GABAergic hypnotics
(Figure 1b). Inhibition of these ascending arousal centers decreases their input to the cortex
and hence decreases cortical activation. The actions of the hypnotic on GABAA interneurons
in the respiratory control network in the ventral medulla are most likely responsible for the
apnea (Feldman et al. 2003).
The atonia observed following bolus administration of propofol may be attributed to its
actions on GABAergic circuits in the spinal cord (Kungys et al. 2009) and in the pontine and
medullary reticular nuclei that control the anti-gravity muscles (Brown et al. 2010) (Figure
2b). This latter hypothesis is consistent with reports of rapid atonia following inadvertent
subarachnoid space and basilar artery injection of local anesthetics during interscalene
blocks (Durrani & Winnie 1991, Dutton et al. 1994), direct injection of a barbiturate into the
mesopontine tegmental area (Devor & Zalkind 2001), and atonia in patients suffering from
pontine strokes and locked-in syndromes (Posner et al. 2007).
The output pathways from the thalamus to the cortex are regulated by major GABAergic
inhibitory inputs from the thalamic reticular nucleus (Jones 2002). Most certainly,
GABAergic hypnotics contribute to sedation and unconsciousness by enhancing inhibitory
activity at these thalamic reticular synapses.
Table 1 summarizes the behavioral and physiological responses of the GABA agonists along
with possible neural circuit mechanisms for these responses.
Analgesia and Sedation: Opioid Receptor Agonists
Opioids can be divided into three categories: natural (morphine, codeine, papaverine),
synthetic (methadone, meperidine, fentanyl, alfentanil, sufentanil, remifentanil), and
semisynthetic (hydromorphone) (Fukuda 2010). Because the primary clinical feature of
opioids is analgesia, i.e., a relief of pain, these drugs are widely used to treat postoperative
pain and to provide analgesia and to serve as an adjunct to maintain unconsciousness during
general anesthesia (Fukuda 2010). Opioids are frequently combined with a benzodiazepine
to provide analgesia and sedation for nonsurgical procedures (Jamieson 1999, Dionne et al.
2001). An awake patient receiving an opioid to treat pain reports analgesia and sedation
(Shapiro et al. 1995, Bowdle 1998). Opioids have a number of side effects, including
respiratory depression, bradycardia, miosis, constipation, nausea, vomiting, euphoria, and
dysphoria (Bowdle 1998).
The principal molecular targets of opioids are the μ, κ, and δ opioid receptors. These three
types of G protein-coupled receptors are expressed in many brain regions, including the
periaqueductal gray (PAG), the rostral ventral medulla (RVM), the basal ganglia (Burn et al.
1995), the amygdala, and the spinal cord (Stein 1995, Dowlatshahi & Yaksh 1997).
Activation of the opioid receptor leads to hyperpolarization of the nerve cell membrane by
inhibiting adenyl cyclase, decreasing conductance of voltage-gated calcium channels, and
opening inward-rectifying potassium channels that allow potassium efflux (Fukuda 2010).
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A nociceptive stimulus, such as a surgical incision, activates the free nerve endings of C-
fibers and/or A-delta fibers, which make excitatory synapses onto projection neurons in the
dorsal horn of the spinal cord (Figure 3a). The axons of the projection neurons cross the
midline of the spinal cord and ascend in the anterolateral fasiculus to synapse in the RVM,
the PAG, the thalamus, the amygdala, and the primary and secondary somatosensory
cortices (Millan 2002). These are the principal components of the ascending nociceptive
pathway. Nociceptive stimulation of the PAG and the RVM initiates descending pathways
that modulate the nociceptive signaling through a combination of descending inhibition and
descending facilitation (Millan 2002). These are the major components of the descending
nociceptive pathways. These sites are also targets of the endogenous opioids, endorphins,
and enkephalins (Millan 2002).
Because inhibition of nociceptive processing leads to decreased arousal, the several
mechanisms through which the opioids achieve their analgesic and antinociceptive effects
are the principal mechanisms through which these drugs alter arousal. Opioids binding to
opioid receptors in the PAG and the RVM leads to activation of the descending nociceptive
pathways, which produces an overall inhibitory effect on nociceptive transmission (Millan
2002) (Figure 3b). One mechanism for activating descending inhibition is through opioid
receptor mediated hyperpolarization of GABAergic inhibitory interneurons in the PAG
(Heinricher & Morgan 1999). These inhibitory neurons synapse onto excitatory neurons that
project to the RVM. Excitatory stimulation of the RVM by the PAG leads to increased firing
of RVM off-cells and decreased firing of RVM on-cells (Heinricher & Morgan 1999). This
pattern of activation in the RVM is associated with descending inhibition of nociception at
the level of peripheral afferent neurons and of the projection neurons in the spinal cord.
Opioids applied directly to the spinal cord produce analgesia by at least two mechanisms
(Figure 3b). Binding of opioids to presynaptic opioid receptors on peripheral afferent
neurons inhibits adenylate cyclase and suppresses voltage-dependent calcium channels and
sub-sequent release of glutamate and neuropeptides such as substance P and calcitonin
(Meunier et al. 1995). Postsynaptic activation of the opioid receptors on the projection
neurons in the dorsal horn initiates an increase in potassium conductance, leading to
hyperpolarization of the nerve cell membrane and, hence, to decreased firing. Opioids may
also produce analgesia by binding to opioid receptors on primary sensory neurons (Stein
1995).
Opioids also alter arousal through their anti-cholinergic effects. For example, during normal
waking, the cholinergic projections from the lateral dorsal tegmental nucleus (LDT) and the
peduculopontine tegmental nucleus (PPT) activate the medial pontine reticular formation
(mPRF) and thalamus (Lydic & Baghdoyan 2005) (Figure 3a). The mPRF in turn provides
excitatory glutamatergic inputs to the thalamus, which sends excitatory inputs to the cortex.
The basal forebrain provides another important source of excitatory cholinergic inputs to the
cortex (McCarley 2007). Fentanyl decreases arousal by decreasing acetylcholine in the
mPRF, whereas morphine decreases arousal by inhibiting the neurons in the LDT, the
mPRF, and the basal forebrain (Mortazavi et al. 1999, Lydic & Baghdoyan 2005) (Figure
3b).
Actions of opioids in the cortex and the limbic system also lead to altered arousal.
Functional imaging studies of pain processing in humans have shown that low-dose
morphine induces euphoria associated with positive blood oxygen level dependent (BOLD)
signal changes in the nucleus accumbens along with a pattern of negative BOLD signal
changes in the cortex similar to that seen with GABAA agonists (Becerra et al. 2006).
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The altered arousal state induced by opioids does not reliably produce complete
unconsciousness even when high doses are administered (Bailey et al. 1985). This is
evidenced by the high incidence of awareness during cardiac surgery for which high-dose
opioids had been the standard anesthetic regimen for many years because of their combined
effects of analgesia, decreased arousal, and cardiovascular stability (Ranta et al. 1996,
Silbert & Myles 2009).
Respiratory depression, the most clinically significant side effect of opioids, is mediated
through opioid binding to μ2 receptors in the medulla (Weil et al. 1975). Reversal of
respiratory depression by using an opioid antagonist also reverses analgesia as well because
both work through the same mechanism (Greer & Ren 2009). Ampakines, AMPA receptor
antagonists, have been shown in rats to counter fentanyl-induced respiratory depression
without significantly altering analgesia and sedation (Greer & Ren 2009, Ren et al. 2009).
These drugs may offer a way of maintaining adequate respiration while providing analgesia
with opioids. Opioids acting at opioid receptors in the gut help explain the decreased
motility and constipation seen with opioid use (Stewart et al. 1978, Greenwood-Van
Meerveld et al. 2004). Nausea and emesis are due in part to binding of these drugs to opioid
receptors in the chemotactic trigger zone (CMTZ) in the area postrema (Takahashi et al.
2007). Other side effects of opioids are likely to be mediated cholinergically. Bradycardia is
likely due to GABAA-mediated disinhibition, leading to activation of cholinergic projections
from the nucleus ambiguus to the sino-atrial node of the heart (Griffoen et al. 2004). Miosis
may result from the direct or indirect anticholinergic effects of the opioids on the Edinger-
Westfall nuclei in the midbrain.
Table 2 summarizes the behavioral and physiological responses of the opioid agonists along
with possible neural circuit mechanisms for these responses.
Analgesia, Hallucinations, and Dissociative Anesthesia: NMDA Receptor
Antagonists
Ketamine, an arylcyclohexylamine, is a congener of phencyclidines that anesthesiologists
use as an analgesic and a hypnotic (Bergman 1999). It is also used as an adjunct to help
maintain general anesthesia and as an alternative to opioids for the management of
perioperative and neuropathic pain.
When a small dose of ketamine is administered, immediate, intense analgesia is the most
apparent clinical feature (Kohrs & Durieux 1998). For this reason, low-dose ketamine is
used commonly in anesthesiology to treat labor pain (Mercier & Benhamou 1998), to
position a patient with lower extremity fracture for placement of a regional block, and to
perform dressing changes in burn patients (Kohrs & Durieux 1998). The patient enters a
dissociative state in which he/she perceives nociceptive stimuli but not as pain (Garfield et
al. 1972, Kohrs & Durieux 1998, Bergman 1999). Auditory and visual hallucinations that
resemble those seen in schizophrenia are common with ketamine (Seamans 2008). This is
why ketamine is used as a pharmacological model of schizophrenia in animals (Olney et al.
1999, Kehrer et al. 2008) and why it is a widely used drug of abuse (Morgan et al. 2009).
Respiratory function is generally preserved at sedative doses of ketamine. In contrast to the
GABAA hypnotics, under ketamine, the EEG (Hayashi et al. 2007, Tsuda et al. 2007) is
active, and both cerebral metabolic rates and blood flow increase (Cavazzuti et al. 1987,
Strebel et al. 1995, Vollenweider et al. 1997) rather than decrease. Other key physiological
effects of ketamine are horizontal nystagmus, pupillary dilation, salivation, lacrimation,
tachycardia, and bronchodilation (Kohrs & Durieux 1998, Reves et al. 2009).
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Ketamine's principal molecular target is the NMDA receptor, a major postsynaptic,
ionotropic receptor for the excitatory neurotransmitter glutamate (Sinner & Graf 2008).
These pharmacologically defined receptors have an obligatory NR1 subunit and a
modulatory NR2 subunit. Channel opening requires that an agonist (glutamate or NMDA)
bind to the NR2 subunit while the coagonist glycine binds to the NR1 subunit (Purves et al.
2008). Experimental evidence suggests that ketamine blocks NMDA receptors by
uncompetitive binding at a location other than the glutamate or glycine sites (Kim et al.
2002).
An understanding of how ketamine alters arousal is provided by strong experimental
evidence that shows that ketamine binds preferentially to NMDA receptors on GABAergic
inhibitory interneurons (Olney et al. 1999, Seamans 2008) (Figure 4).By selectively down-
regulating GABAergic inhibition, ketamine disinhibits pyramidal neurons, leading to an
altered arousal state consisting of abberant excitatory activity in multiple brain areas.
Hallucinations and the dissociative state most likely result because multiple brain areas such
as the cortex, the hippocampus and the limbic system are allowed to communicate through
abberant activity that lacks normal spatial and temporal coordination. Benzodiazepines,
GABAA agonists, are commonly administered with ketamine to help mitigate the
hallucinations by possibly helping to restore some of the inhibitory activity in the affected
brain regions. The increased pyramidal activity helps explain the increased EEG activity, the
cerebral metabolic rate, and the cerebral blood flow seen under ketamine.
The analgesic effects of ketamine are due in part to its dissociative effects and to its
blockade of NMDA receptors in the spinal cord, most notably on peripheral afferent neurons
in the nociceptive pathways (Figure 4b) (Oye et al. 1992, Sinner & Graf 2008). Ketamine
may also act at opioid receptors (Finck & Ngai 1982). Because certain types of neuropathic
pain may be mediated in part by hyperactivity in NMDA circuits (Hocking & Cousins
2003), ketamine is widely used as a treatment for this disorder. Chronic regional pain
syndrome (CRPS) is a type of neuropathic pain that may develop following trauma to an
extremity that results in nerve damage (Kiefer et al. 2008). Although the initial injury may
not be severe, with time, the pain associated with the injury becomes more intense and
extends beyond the area that was originally affected. Sufferers from severe CRPS complain
of constant burning sensations across large parts of their body.
An experimental therapy, the ketamine coma, is being used to treat severe CRPS (Kiefer et
al. 2008, Becerra et al. 2009). The ketamine coma, which is not currently approved in the
United States, is conducted by inducing and maintaining general anesthesia with a
continuous intravenous infusion of ketamine, intubation, and mechanical ventilation for five
to seven days. Following cessation of ketamine, some patients report dramatic reductions in
pain symptoms that can last from a few days to several months. Although the mechanism of
the effect remains unclear, it is possible that the weeklong central nervous system blockade
of the NMDA receptors helps break the wind-up and central sensitization cascade believed
to underlie neuropathic pain syndromes (Costigan et al. 2009). Patients are unresponsive
during the ketamine coma. However, unlike the coma period resulting from a brain injury, or
more standard general anesthesia, about which patients typically have no recall, patients
emerging from ketamine coma recall vivid and often disturbing hallucinations (Kiefer et al.
2008).
Recent reports that low-dose ketamine can provide immediate symptom relief in patients
suffering from chronic bipolar disorders and chronic depression have stimulated significant
interest in another way this drug alters arousal (Zarate et al. 2006). In contrast to standard
therapies for these disorders, which may require weeks to months to produce an effect,
ketamine's effects can begin within 40 minutes and last for up to 7 days. This effect may be
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due to a change in the AMPA to NMDA receptor activity ratio (Maeng et al. 2008), to
ketamine-induced synaptogenesis (Li et al. 2010), or to the possibility that the excitatory
state induced by ketamine, through its actions on inhibitory interneurons, may be providing
chemically what electroconvulsive therapy (ECT) provides electrically.
Ketamine-induced nystagmus appears to be the consequence of the drug's differential effects
in the frontal cortex, the cerebellum, and the vestibular nuclei (Porro et al. 1999).
Lacrimation and salivation seen with ketamine possibly reflect increased
parasympathetically mediated activity in the inferior and superior salivatory nuclei (Purves
et al. 2008), whereas pupillary dilation, tachycardia, and bronchodilation most likely reflect
increased sympathetic output from the nucleus tractus solitarius (Ogawa et al. 1993,
Freeman 2008). These symptoms, we speculate, may be due to NMDA-mediated
disinhibition of GABAergic interneurons in these areas that leads to coactivation of the
parasympathetic and sympathetic systems.
Table 3 summarizes the behavioral and physiological responses of the ketamine along with
possible neural circuit mechanisms for these responses.
Pharmacological Non-REM Sleep: Alpha Adrenergic Receptor Agonists
Dexmedetomidine and clonidine belong to the imidazole subclass of α2 adrenergic receptor
agonists (Coursin & Maccioli 2001). Dexmedetomidine is a sedative whose indicated uses
are for short-term sedation (<24 h) for mechanically ventilated patients in the intensive care
unit (Gerlach & Dasta 2007) and for sedation of nonintubated patients for surgical and
medical procedures (Hospira 2009). It is now being used off-label as an adjunct for general
anesthesia (Carollo et al. 2008, Chrysostomou & Schmitt 2008). Sedation with
dexmedetomidine is noticeably different from sedation with GABAA agonists because
patients are readily arousable and have little to no respiratory depression (Hsu et al. 2004).
Basic science studies have demonstrated that a primary target at which dexmedetomidine
acts to alter arousal is the α2 receptors on neurons emanating from the locus coeruleus (LC)
(Correa-Sales et al. 1992, Chiu etal. 1995, Mizobe et al. 1996). Binding of dexmedetomidine
to this G protein–coupled receptor initiates inwardly rectifying potassium currents that allow
potassium efflux and inhibition of voltage-sensitive calcium channels. The net
hyperpolarization of the LC neurons leads to a decrease in norepinephrine release from these
neurons (Jorm & Stamford 1993, Nacif-Coelho et al. 1994, Nelson et al. 2003).
The behavioral effects of dexmedetomidine are consistent with its proposed mechanisms of
action in the LC. Basic science studies suggest that, during the wake state, the LC provides
norepinephrine-mediated inhibition to the POA in the hypothalamus (Figure 5a) (Osaka &
Matsumura 1994, Saper et al. 2005, Lu et al. 2006). The LC also provides key
adrenergically mediated excitatory inputs to the basal fore-brain, intralaminar nucleus of the
thalamus, and the cortex (España & Berridge 2006). POA neurons releasing GABA and the
inhibitory neurotransmitter galanin inhibit the ascending arousal centers in the midbrain,
upper pons, and hypothalamus (Sherin et al. 1998, Saper et al. 2005). Thus inhibition of
POA neurons promotes wakefulness. At the onset of sleep, the LC is inhibited, and its
noradrenergically mediated inhibition of the POA ceases. As a consequence, the POA
becomes active and its GABAergic and galaninergic neurons inhibit the ascending arousal
centers to provide a possible mechanism for initiating non-REM sleep.
It is plausible that decreased norepinephrine release from the LC induced by
dexmedetomidine disinhibits the POA (Nelson et al. 2002, 2003).Therefore, the disinhibited
POA inhibits the ascending arousal pathways, and sedation ensues (Figure 5b). Blocking
norepinephrine release from the LC would also contribute to sedation due to decreased
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excitatory inputs to the basal forebrain, to the intralaminar nucleus of the thalamus, and to
the cortex (España & Berridge 2006). A clinical study has demonstrated a close resemblance
between EEG spindles observed in dexmedetomidine-induced sedation and those observed
during stage 2 non-REM sleep (Huupponen et al. 2008). Subjects were easily arousable from
dexmedetomidine-induced sedation and from non-REM sleep. These basic science and
clinical studies help us understand why the altered arousal state of dexmedetomidine-
induced sedation closely resembles non-REM sleep.
Clonidine, injected intrathecally, is commonly used as an adjunct in postoperative pain
therapy (Andrieu et al. 2009). Clonidine acts at α2 receptors in the descending nociceptive
pathways in the spinal cord to enhance antinociception (Figure 5b). The α2 receptor agonist
xylazine is frequently administered with ketamine to provide general anesthesia for animal
surgeries (Rodrigues et al. 2006).
Table 4 summarizes the behavioral and physiological responses of the α2 agonists along
with possible neural circuit mechanisms for these responses.
Neuroleptic Anesthesia: Dopamine Receptor Antagonists
The butyrophenones, haloperidol and droperidol, are dopamine antagonists that have been
used in anesthesiology (Hardman 2001) as sedatives, anesthetic adjuncts, and antiemetics.
The altered arousal state induced by these drugs is insufficient for their use as sole anesthetic
agents. Butyrophenones have been used in combination with opioids—haloperidol with
phenoperidine and droperidol with fentanyl—to create a state of neuroleptic anesthesia
characterized by unresponsiveness with eyes open, analgesia, and decreased mobility
(catalepsy) with maintenance of ventilation and cardiovascular stability (Corssen et al.
1964). Neuroleptic anesthesia is no longer used because not infrequently patients
complained of feeling locked in: being aware of what transpired during the surgery with
substantial pinned-up emotion that they could not express (Klausen et al. 1983, Linnemann
et al. 1993, Klafta et al. 1995).
The butyrophenones, used almost exclusively now as antiemetics (Apfel et al. 2009), can
cause Parkisonian symptoms (bradykinesia, tremor, muscle rigidity, blunted affect) at both
low (Rivera et al. 1975, Melnick 1988) and high (Lieberman et al. 2008) doses. In the
United States, droperidol carries a controversial black label warning from the US FDA
because of rare reports of cardiac dysrhythmias following its use in high doses (FDA 2001,
Dershwitz 2003). Use of droperidol at any dose requires perioperative electrocardiogram
monitoring.
Basic science studies haveshown that the butyrophenones are dopamine receptor
antagonists. The five types of dopamine receptors are all 7-transmembrane, G protein–
coupled receptors that are divided into two classes: D1 and D2 (Girault & Greengard 2004).
The D1 receptors mediate excitation by activating G-proteins that stimulate cyclic AMP
(cAMP) synthesis. In contrast, the D2 receptors mediate inhibition by activation of G-
proteins that inhibit cAMP synthesis, suppress Ca2+ currents, and activate receptor-operated
potassium currents.
The brain has three principal dopaminergic pathways (Figure 6a). The nigrostrial pathway,
which projects from the pars compacta of the substantia nigra to the striatum, is a
component of the basal ganglia that is crucial for movement control (Graybiel 1991,
Graybiel et al. 1994). Patients suffering from Parkinson's disease have slow movements, a
resting tremor, rigidity in all extremities, and minimal facial expressions due to a lack of
dopamine production in the substantia nigra (Obeso et al. 2008). The mesolimbic pathway
that projects from the ventral tegmen-tum to the nucleus accumbens, amygdala, and
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hippocampus plays a key role in processing reward, motivation, emotion, and reinforcement.
The mesocortical pathway, which projects from the ventral tegmentum to the frontal cortex,
complements the function of the mesolimbic pathway and aids in cognition (Obeso et al.
2008).
The cataleptic state induced by the butyrophenones can be attributed to their binding to D1
and D2 receptors in the striatum, leading to a net increase in inhibitory output from the
globus pallidus to the thalamus and, as a consequence, to reduced excitation of the motor
cortex (Lieberman et al. 2008) (Figure 6b). Although, the mechanism may not be as simple
as stated, these results are consistent with the direct- and indirect-pathway models of
Parkinson's disease. The muted affect and emotion observed in patients receiving a
butyrophenone may be due to loss of facial muscle control induced by the drugs' dopamine
antagonistic actions in the nigrostriatal pathways (Tickle-Degnen & Lyons 2004, Lieberman
et al. 2008). Sedation most likely results from the action of the drugs in the mesolimbic and
mesocortical pathways (Figure 6b). The antiemetic effects of the butyrophenones are most
likely multifactorial:blocking dopamine receptors in the CMTZ of the area postrema (Apfel
2009), blocking histaminergic inputs to the nucleus of the tractus solitarius (NTS), blocking
serotinergic inputs to the NTS and CMTZ, and blocking cholinergic effects in the dorsal
motor nucleus of the vagus (Peroutka & Synder 1980 1982; Scuderi 2003).
Although not broadly appreciated in anesthesiology, the opioids are perhaps the most widely
used dopaminergic antagonist in clinical practice. Basic science studies have shown that
opioid binding to μ and κ opioid receptors in the striatum and substantia nigra inhibit
dopamine release (Havemann et al. 1982, Burn et al. 1995). This decrease in striatal
dopamine levels can contribute to a state of decreased mobility similar to that seen in
Parkinson's disease. This observation offers insight into why awareness has been more likely
under high-dose fentanyl anesthesia. Fentanyl binds to opioid receptors in the rostral ventral
medulla to provide both analgesia (Yaksh 1997) and activation of parasympathetic outflow
(Griffioen et al. 2004). In high dose, its antidopaminergic effects are more likely to be
present also. This combination of analgesia, catalepsy, parasympathetic activation
(sympathetic quiescence), and muted stress response is likely to be part of the drug-induced
locked-in state about which patients who received Innovar complained (Klafta et al. 1995).
Hence, if high-dose fentanyl is used with few or no additional anesthetic agents that have
cortical effects, a patient can be comfortable, immobile, show little to no stress response, yet
remain aware.
Table 5 summarizes the behavioral and physiological responses of the dopaminergic
antagonist along with possible neural circuit mechanisms for these responses.
Implications and Future Directions
Five altered states of arousal induced by intravenous anesthetic drugs can be understood by
analyzing the behavioral and physiological effects of the drugs in relation to the molecular
targets in specific neural circuits at which they are believed to act. In each case, we can
suggest how the altered arousal state is created by the drug's actions at multiple sites in the
central nervous system. Hence, these states are neither mysterious nor indecipherable. This
systems neuroscience paradigm suggests a framework for improving research, practice, and
education in anesthesiology and for relating general anesthesia to other altered states of
arousal.
Anesthesiology: Research, Practice, and Education
Further clinical and basic systems neuroscience studies of general anesthesia's altered
arousal states that use the latest functional neuroimaging, neurophysiological, behavioral
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and molecular techniques will have important implications for anesthesiology and for
neuroscience. A clearer understanding of the molecular targets and the neural circuits is
needed to design novel site-specific anesthetic drugs that produce desired behavioral and
physiological changes in a controlled manner while obviating side effects.
For example, postoperative nausea and vomiting remain two of the most vexing side effects
following general anesthesia. Postoperative cognitive dysfunction is now recognized as a
major concern following surgery with general anesthesia for at least 30% of patients (Monk
et al. 2008). For the elderly, the incidence can be higher than 40% (Monk et al. 2008, Price
et al. 2008). Although the mechanisms are multifactorial and some are not related to the
anesthetic drugs, evidence is accruing to suggest how anesthetics contribute to postoperative
cognitive dysfunction.
Opioids are strongly associated with postoperative delirium, in part because of their
anticholinergic effects (Marcantonio et al. 1994), which may be worst in the elderly (Hshieh
et al. 2008, Campbell et al. 2009). Similarly, prolonged exposure of intensive care unit
patients to benzodiazepines is associated with delirium, prolonged intensive care unit and
hospital stays, and increased mortality (Pandharipande et al. 2007). These findings suggest
that prolonged exposure to the nonphysiological inhibitory state created by GABAA agonists
in the central nervous system may be deleterious. In contrast, the recently demonstrated
benefits of dexmedetomidine as an intensive care unit sedative compared with lorazepam
can be attributed, in part, to the fact that the sedative actions of the former are more site
specific (Pandharipande et al. 2007).
How certain anesthetics may contribute to the high prevalence of postoperative delirium in
children (Vlajkovic & Sindjelic 2007) and the potentially adverse effect of repeated
anesthetic exposures in children on central nervous system development are becoming
increasingly important concerns of the United States Food and Drug Administration and the
International Anesthesia Research Society (Int. Anesth. Res. Soc. 2010). Ketamine and other
NMDA antagonists contribute to apoptosis in the newborn brains of animals, leading to
recent recommendations to reconsider the use of these drugs in neonates (Anand 2007,
Mellon et al. 2007). Similarly, benzodiazepines are frequently given as sedatives to children
who require multiple reconstructive surgeries following burn injuries (Stoddard et al. 2002),
yet the same drugs are used in experimental models of nervous system development to probe
the role of GABA in excitatory-inhibitory balance (Hensch 2004).
Successful use of systems neuroscience concepts in the daily practice of anesthesiology will
require more in-depth training of anesthesiologists in neuroanatomy, neurophysiology, and
neuropharmacology to bridge the current gap between clinical management of general
anesthesia and the understanding of the neuro-physiological and molecular mechanisms that
underlie those management decisions. This improved understanding will allow more astute
interpretations of findings from clinical examinations of patients under general anesthesia,
which when coupled with results from ongoing systems neuroscience studies, should lead to
improved, neurophysiologically based approaches to producing general anesthesia and to
monitoring the states of the brain under general anesthesia. In this way, anesthesiologists can
avoid even rare though potentially traumatic events, such as awareness under general
anesthesia (Avidan et al. 2008, Errando et al. 2008).
General Anesthesia and Other Altered Arousal States
We began our systems neuroscience analysis by defining general anesthesia as changes in
behavioral states with maintenance of homeostasis because there is not a universally
accepted definition of general anesthesia. This is due in part to the difficulty
anesthesiologists have of being able to state accurately their well-formed empirical
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understanding of this condition. For example, confusion arises because anesthesiologists use
the term sleep as a nonthreatening description of general anesthesia when speaking with
patients. A level of general anesthesia appropriate for surgery is not sleep but rather a coma
(Brown et al. 2010). However, like sleep, general anesthesia is reversible and can allow
dreaming (Leslie & Skrzypek 2007, Errando et al. 2008, Samuelsson et al. 2008). The
concept of coma is less comforting and harder for patients to understand than the notion of
sleep. Despite several descriptions of the differences between sleep and general anesthesia
(Lydic & Baghdoyan 2005, Brown et al. 2010), uses of the term sleep to describe the altered
arousal states of general anesthesia appear in anesthesiology (Reves et al. 2009), medical
(Gawande et al. 2008), and legal (Dershwitz & Henthorn 2008) articles.
Using the systems neuroscience framework to define altered arousal states in terms of
behavioral and physiological responses, molecular targets and neural circuits can facilitate
cross-disciplinary communication and research on how altered arousal states induced by
anesthetic agents relate to the fundamental questions of consciousness (Crick & Koch 2003,
Mashour 2006) and how they compare with other altered arousal states such as sleep (Lydic
& Baghdoyan 2005, McCarley 2007, Alkire et al. 2008, Franks 2008), sleep aided by
pharmacologic agents (NIH Consens. Dev. Conf. 1984), the stages of coma (Giacino et al.
2002), schizophrenia (Olney et al. 1999), seizures (Blumenfeld & Taylor 2003), locked-in
states (Posner et al. 2007), drug-induced high or paradoxical excitation (Brown et al. 2010),
meditation (Lazar et al. 2005), hypnosis (Vanhaudenhuyse et al. 2009), hibernation (Revel et
al. 2007), and suspended animation (Blackstone et al. 2005). Many of these altered arousal
states have analogsin pharmacologic states induced by anesthetic drugs.
Summary
General anesthesia is a nonphysiological, drug-controlled condition created so that surgical
and medical therapies can be provided safely and humanely. The fundamental question for
anesthesiology research is how can this state be created by making physiologically sound,
reversible manipulations of the neural circuits in the central nervous system? The systems
neuroscience paradigm we used to analyze general anesthesia–induced states of altered
arousal offers an integrated framework for formulating and answering this question.
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Glossary
Sedation a pharmacologically induced state of decreased movement,
anxiolysis, decreased arousal with slow and/or incoherent
responses to verbal commands
Hypnotic any anesthetic agent used to induce unconsciousness in a
patient
Electroencephalogram
(EEG) oscillations
EEG oscillatory patterns are characterized in terms of 5
different frequency bands delta (0–4 Hz), theta (4–8 Hz),
alpha (8–12 Hz), beta (13–25 Hz), gamma (40–80 Hz)
Induction initiation of general anesthesia achieved usually by
administering a bolus dose of a hypnotic to render a patient
unconscious
Smooth pursuit the ability of the eyes to track closely a moving object with
an uninterrupted change in gaze
Burst suppression an EEG oscillation pattern composed of high-frequency
activity interspersed with periods of isoelectricity (flatlines)
Myoclonus brief involuntary twitching in a muscle or group of muscles
Maintenance sustaining a state of general anesthesia sufficient for a
patient to receive surgical or medical procedures
Interscalene block regional anesthesia for the brachial plexus achieved by
injecting a local anesthetic through a needle inserted
between the anterior and middle interscalene muscles at C6
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Figure 1.
GABAergic signaling during the awake state (a) and during propofol administration (b). (a)
A cortical interneuron during wakefulness mediating control of pyramidal neurons and being
modulated by ascending arousal centers. Also shown are inhibitory projections from the
POA to the arousal-promoting nuclei. (b) Propofol enhances GABAergic transmission in the
cortex and at the inhibitory projections from the POA to the arousal centers. Abbreviations:
5HT, serotonin; ACh, acetylcholine; DA, dopamine; DR, dorsal raphe; GABA, gamma
aminobutyric acid; Gal, galanin; His, histamine; LC, locus coeruleus; LDT, laterodorsal
tegmental area; LH, lateral hypothalamus; NE, norepinephrine; POA, preoptic area; PPT,
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pedunculopontine tegmental area; TMN, tuberomamillary nucleus; vPAG, ventral
periaquaductal gray.
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Figure 2.
Sites of major nuclei that regulate arousal and respiration. (a) A sagittal diagram of a human
brain with cholinergic nuclei (green), monoaminergic nuclei (dark blue), GABAergic and
galanergic nuclei (red), orexin nuclei (pink), and the respiratory nuclei (light blue). (b) Sites
of major respiratory and motor relay nuclei in the pons and medulla. Abbreviations: 5HT,
serotonin; ACh, acetylcholine; DA, dopamine; DRG, dorsal respiratory group; GABA,
gamma aminobutyric acid; Gal, galanin; His, histamine; LC, locus coeruleus; LDT,
laterodorsal tegmental area; LH, lateral hypothalamus; NE, norepinephrine; POA, preoptic
area; PPT, pedunculopontine tegmental area; TMN, tuberomamillary nucleus; VAG, ventral
periaquaductal gray; VRG, ventral respiratory group.
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Figure 3.
Sites of opioid receptor effects during the awake state (a) and during opioid administration
(b). (a) Normal cholinergic signaling during wakefulness and normal nociceptive signaling
from the spinal cord to brain stem. (b) Illustrates opioid-induced decrease in arousal through
a decrease in cholinergic signaling and the mechanisms of opioid-induced analgesia.
Abbreviations: ACh, acetylcholine; DRG, dorsal root ganglia; Glu, glutamate; LDT,
laterodorsal tegmental area; mPRF, medial pontine reticular formation; NE, norepinephrine;
PAF, peripheral afferent fiber; PAG, periaquaductal gray; PN, projection neuron; PPT,
pedunculopontine tegmental area; RVM, rostal ventral medulla.
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Figure 4.
NMDA receptor signaling during the awake state (a) and during ketamine administration
(b). (a) Normal glutamatergic regulation of GABAergic interneuron signaling during
wakefulness and normal pain pathway signaling. (b) Ketamine blockage of GABAergic
interneuron inhibition and ketamine-induced mechanism of analgesia. Abbreviations: DRG,
dorsal root ganglia; GABA, gamma aminobutyric acid; Glu, glutamate; PAF, peripheral
afferent fiber; PN, projection neuron.
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Figure 5.
Alpha adrenergic signaling during the awake state (a) and during dexmedetomidine or
clonidine administration (b). (a) Normal adrenergic signaling from the LC during
wakefulness and normal pain signaling during wakefulness from the spinal cord to the brain
stem. (b) Dexmedetomidine-induced loss of consciousness through NE mediated inhibition
of the POA and decreased noradrenergic signaling in the thalamus and cortex. Clonidine-
induced analgesia through enhanced inhibitory activity in the descending pain pathway.
Abbreviations: 5HT, serotonin; ACh, acetylcholine; DA, dopamine; DRG, dorsal root
ganglia; GABAA, gamma aminobutyric acid receptor subtype A; Gal, galanin; His,
histamine; ILN, intralaminar nucleus of the thalamus; LC, locus coeruleus; LDT,
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laterodorsal tegmental area; NE, norepinephrine; PAF, peripheral afferent fiber; PN,
projection neuron; POA, preoptic area; PPT, pedunculopontine tegmental area; RVM, rostral
ventral medulla; TMN, tuberomamillary nucleus; vPAG, ventral periaquaductal gray.
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Figure 6.
Dopamine signaling during the awake state (a) and during haloperidol administration (b). (a)
Normal dopamine signaling during wakefulness. (b) Haloperidol effects on dopamine
signaling. Abbreviations: GP, globus pallidus; NAcc, nucleus accumbens; SN, substantia
nigra; VTA, ventral tegmental area.
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Table 1
Summary of the behaviors, physiological responses, and neural circuits for the actions of
GABAA agonistsa
Drugs
Behaviors and physiological
responses Possible neural circuit mechanism Receptors
Propofol, Etomidate,
Thiopental, Methohexital
Unconsciousness and sedation Potentiation of GABAergic interneurons in the cortex,
the thalamic reticular nucleus, and the arsousal centers
in the midbrain and pons
GABAA
Seizures Potentiation of GABAergic interneurons locally in the
cortex
Apnea GABAergic inhibition of brain stem respiratory
control areas (ventral medulla)
Atonia Inhibition of the pontine and medullary reticular
nuclei that control antigravity muscles and inhibition
of spinal motor neurons
Myoclonus Possible effects on primary motor pathways
Loss of corneal and oculocephalic
reflexes
GABAergic inhibition in the brain stem of the
oculomotor, abducens and trochlear nuclei, the
trigeminal nuclei, and the motor nuclei of the seventh
cranial nerve
aAbbreviations: GABAA, gamma aminobutyric acid type A.
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Table 2
Summary of the behaviors, physiological responses, and neural circuits for the actions of
opioid agonistsa
Drugs
Behavioral and physiological
responses Possible neural circuit mechanism Receptors
Morphine, Fentanyl,
Hydromorphone, Remifentanil
Analgesia, Antinociception Activation of descending inhibitory pathways through
disinhibition of GABAergic interneurons in the
periacequeductal gray and rostal ventral medulla
Inhibition of ascending pain pathways in the spinal
cord pre-and postsynaptically in peripheral neurons
and ascending projection neurons, respectively
Opioid
Respiratory depression μ2-opioid mediated inhibition of brain stem
respiratory control areas (ventral medulla)
Nausea and emesis δ-opioid receptor mediated activity in chemotactic
trigger zone in area postrema
Sedation Reduced arousal due to antinociception
Bradycardia Activation of projections from nucleus ambiguous to
sino-atrial node in heart
Sedation Anticholinergic activity in lateral dorsal tegmental
nucleus, pedunculopontine tegmental nucleus, median
pontine reticular formation, and basal forebrain
ACh
Miosis Anticholinergic activity possibly in Edinger-Westfall
nuclei
Insomnia Reduction in brain levels of adenosine, required to
initiate sleep
Adenosine
Catalepsy Catalepsy induced by dopaminergic antagonist
activity (see Dopamine Antagonist section below)
Dopamine
aAbbreviations: ACh, acetylcholine; GABAA, gamma aminobutyric acid type A.
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Table 3
Summary of the behaviors, physiological responses, and neural circuits for the actions of
ketamine (NMDA receptor antagonist)a
Drugs
Behavioral and physiological
responses Possible neural circuit mechanisms Receptors
Ketamine Analgesia Blockade of NMDA-mediated nociceptive stimuli in the dorsal horn of the
spinal cord
NMDA
Dissociative state hallucinations Preferential binding to NMDA receptors on GABAergic inhibitory
interneurons in cerebral cortex, hippocampus, and limbic structures,
resulting in disinhibition and aberrant excitatory activity in these areas.
Hallucinations are treated with benzodiazepines, which is consistent with a
GABA-mediated mechanism
Antidepressant effect Increased neurogenesis and synaptogenesisChange in the NMDA to AMPA
receptor activity ratioNMDA-mediated cortical activation by inhibition of
GABAergic inhibitory interneurons (chemical ECT induced by
disinhibition)
Lacrimation and salivation Increased parasympathetic stimulation of inferior and superior salivatory
nuclei due to NMDA-mediated inhibition of GABAergic interneurons
(disinhibition)
Pupillary dilation, tachycardia,
bronchodilation
Increased sympathetic output from nucleus tractus solitarius due to NMDA-
mediated inhibition of GABAergic interneurons (disinhibition)
Nystagmus Increased activity in cortical areas generating saccades (disinhibition via
NMDA inhibition of GABA interneurons) combined with decreased
activity in cerebellum and brain stem reticular formation and medial
vestibular nuclei (direct inhibition of NMDA neurons)
aAbbreviations: AMPA, 2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl)propanoic acid; ECT, electroconvulsive therapy; GABAA, gamma
aminobutyric acid type A; NMDA: N-methyl D-aspartate.
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Table 4
Summary of the behaviors, physiological responses, and neural circuits for the actions of
alpha receptor agonistsa
Drugs
Behavioral and
physiological
responses Possible neural circuit mechanisms Receptors
Dexmedetomidine Sedation mimicking
non-REM sleep
Hyperpolarization of LC reducing inhibitory output to POA, allowing POA to
inhibit multiple ascending arousal systems (PPT/LDT, vPAG, TMN, Raphe,
LC) by GABA and galanin projectionsReduction of NE-mediated activation
of the cortex, the ILN of the thalamus, and the BF
α2 adrenergic
Clonidine Analgesia Inhibition of descending pain facilitation pathway achieved by blocking
presynaptic NE release in excitatory interneuron in the spinal cord
aAbbreviations: BF, basal forebrain; GABAA, gamma aminobutyric acid type A; ILN, intralaminar nucleus; LC, locus coeruleus; LDT,
laterodorsal tegmental area; NE, norepinephrine; PPT, pedunculopontine tegmental area; TMN, tuberomamillary nucleus; POA preoptic area;
vPAG, ventral periaquaductal gray.
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Table 5
Summary of the behaviors, physiological responses, neural circuits, and receptors for the
actions of dopamine antagonists
Drugs
Behavioral and physiological
responses Possible neural circuit mechanisms Receptors
Haloperidol, Droperidol Antinausea, antiemesis Blockade of D2 receptors in chemotactic trigger zone in area
postrema
Dopamine
Catalepsy, tremor, rigidity Blockade of D1 and D2 receptors in striatum leading to a net
increase in inhibition from globus pallidus to thalamus, leading
to reduced activity in motor cortex
Loss of affect and emotional
expression
Loss of facial muscle control due to antidopaminergic activity
in nigrostriatal pathway and decreased affect from actions in
mesolimbic and mesocortical pathways
Sedation Combined inhibition of arousal, mesolimbic and mesocortical
dopaminergic pathways
Antinausea, antiemesis Antihistaminergic activity in nucleus tractus solitarius Histamine
Antinausea, antiemesis Antiserotinergic activity in nucleus tractus solitarius and
chemotactic trigger zone
Serotonin
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